Literature DB >> 32140281

Levels of Soluble Urokinase Plasminogen Activator Receptor in Pediatric Lower Respiratory Tract Infections.

Hale Çitlenbik1, Emel Ulusoy1, Anıl Er1, Aykut Çağlar1, Fatma Akgül1, Tuncay Küme2, Durgül Yılmaz1, Murat Duman1.   

Abstract

Background: Lower respiratory tract infections (LTRIs) are the most common cause of pediatric emergency department visits and are associated with significant morbidity and mortality. The aim of this study was to evaluate the soluble urokinase plasminogen activator receptor (suPAR) levels in pediatric patients with LRTIs and to investigate the correlation of suPAR with disease severity.
Methods: This is a prospective case-control study of children with LTRIs. Demographic data, diagnoses, vital signs, disease severity scores, length of hospital stay, laboratory findings, and viral polymerase chain reaction results for nasopharyngeal aspirates were recorded. Blood samples for suPAR were collected and assessed by enzyme-linked immunosorbent assay.
Results: There were 94 patients with LTRIs and 32 children in the control group. Patients were further subdivided into 2 groups based on diagnosis of acute bronchiolitis (n: 31, 33%) or pneumonia (n: 63, 67%). The median levels of suPAR were significantly higher in patients with LTRIs than in healthy controls (4.3 and 3.5 ng/mL, respectively; P = 0.003). There was an association between suPAR levels and disease severity in pneumonia patients. suPAR values were higher in patients with severe pneumonia than mild pneumonia (5.5 and 3.6 ng/mL, respectively; P < 0.001).
Conclusion: We have shown that suPAR levels increased in patients with LTRIs and suPAR values were higher in patients with severe pneumonia than mild pneumonia. Further studies with large case series are needed to clarify the role of suPAR levels in children with LTRIs. Copyright 2019, Mary Ann Liebert, Inc., publishers.

Entities:  

Keywords:  bronchiolitis; children; pneumonia; suPAR

Year:  2019        PMID: 32140281      PMCID: PMC7057059          DOI: 10.1089/ped.2018.0982

Source DB:  PubMed          Journal:  Pediatr Allergy Immunol Pulmonol        ISSN: 2151-321X            Impact factor:   1.349


  29 in total

1.  Ralston SL, Lieberthal AS, Meissner HC, et al. Clinical Practice Guideline: The Diagnosis, Management, and Prevention of Bronchiolitis. Pediatrics. 2014;134(5):e1474-e1502.

Authors:  S L Ralston; A S Lieberthal; H C Meissner
Journal:  Pediatrics       Date:  2015-10       Impact factor: 7.124

2.  British Thoracic Society guidelines for the management of community acquired pneumonia in children: update 2011.

Authors:  Michael Harris; Julia Clark; Nicky Coote; Penny Fletcher; Anthony Harnden; Michael McKean; Anne Thomson
Journal:  Thorax       Date:  2011-10       Impact factor: 9.139

3.  Plasma concentrations of soluble urokinase-type plasminogen activator receptor are increased in patients with malaria and are associated with a poor clinical or a fatal outcome.

Authors:  Sisse R Ostrowski; Henrik Ullum; Bamenla Q Goka; Gunilla Høyer-Hansen; George Obeng-Adjei; Bente K Pedersen; Bartholomew D Akanmori; Jørgen A L Kurtzhals
Journal:  J Infect Dis       Date:  2005-03-14       Impact factor: 5.226

4.  Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection.

Authors:  N Sidenius; C F Sier; H Ullum; B K Pedersen; A C Lepri; F Blasi; J Eugen-Olsen
Journal:  Blood       Date:  2000-12-15       Impact factor: 22.113

5.  Spectrum and frequency of illness presenting to a pediatric emergency department.

Authors:  M M Massin; J Montesanti; P Gérard; P Lepage
Journal:  Acta Clin Belg       Date:  2006 Jul-Aug       Impact factor: 1.264

6.  Soluble urokinase receptor (uPAR, CD 87) is present in serum and cerebrospinal fluid in patients with neurologic diseases.

Authors:  Juan Carlos Garcia-Monco; James L Coleman; Jorge L Benach
Journal:  J Neuroimmunol       Date:  2002-08       Impact factor: 3.478

7.  Enhanced levels of urokinase plasminogen activator and its soluble receptor in common variable immunodeficiency.

Authors:  Børre Fevang; Jesper Eugen-Olsen; Arne Yndestad; Frank Brosstad; Klaus Beiske; Pål Aukrust; Stig S Frøland
Journal:  Clin Immunol       Date:  2009-02-15       Impact factor: 3.969

8.  Soluble urokinase receptor levels in plasma during 5 years of highly active antiretroviral therapy in HIV-1-infected patients.

Authors:  Sisse R Ostrowski; Terese L Katzenstein; Timo Piironen; Jan Gerstoft; Bente K Pedersen; Henrik Ullum
Journal:  J Acquir Immune Defic Syndr       Date:  2004-04-01       Impact factor: 3.731

9.  Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients.

Authors:  Alexander Koch; Sebastian Voigt; Carsten Kruschinski; Edouard Sanson; Hanna Dückers; Andreas Horn; Eray Yagmur; Henning Zimmermann; Christian Trautwein; Frank Tacke
Journal:  Crit Care       Date:  2011-02-16       Impact factor: 9.097

10.  Soluble urokinase plasminogen activator receptor (suPAR) is a novel, independent predictive marker of myocardial infarction in HIV-1-infected patients: a nested case-control study.

Authors:  L J H Rasmussen; A Knudsen; T L Katzenstein; J Gerstoft; N Obel; N R Jørgensen; G Kronborg; T Benfield; A Kjaer; J Eugen-Olsen; A-M Lebech
Journal:  HIV Med       Date:  2015-09-14       Impact factor: 3.180

View more
  2 in total

1.  suPAR Cut-Offs for Risk Stratification in Patients With Symptoms of COVID-19.

Authors:  Izzet Altintas; Jesper Eugen-Olsen; Santeri Seppälä; Jens Tingleff; Marius Ahm Stauning; Nora Olsen El Caidi; Sanaá Elmajdoubi; Hejdi Gamst-Jensen; Mette B Lindstrøm; Line Jee Hartmann Rasmussen; Klaus Tjelle Kristiansen; Christian Rasmussen; Jan O Nehlin; Thomas Kallemose; Harri Hyppölä; Ove Andersen
Journal:  Biomark Insights       Date:  2021-08-15

2.  Evaluation of Plasma Soluble Urokinase Plasminogen Activator Receptor Levels in Patients With COVID-19 and Non-COVID-19 Pneumonia: An Observational Cohort Study.

Authors:  Dimitrios Velissaris; Maria Lagadinou; Themistoklis Paraskevas; Eleousa Oikonomou; Vasileios Karamouzos; Sofia Karteri; Dimitrios Bousis; Nikolaos Pantzaris; Konstantinos Tsiotsios; Markos Marangos
Journal:  J Clin Med Res       Date:  2021-09-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.